- Home
- EML vs CGEN Comparison
EML vs CGEN Comparison
Compare EML & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EML
- CGEN
- Stock Information
- Founded
- EML 1858
- CGEN 1993
- Country
- EML United States
- CGEN Israel
- Employees
- EML N/A
- CGEN N/A
- Industry
- EML Industrial Machinery/Components
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EML Consumer Discretionary
- CGEN Health Care
- Exchange
- EML Nasdaq
- CGEN Nasdaq
- Market Cap
- EML 161.7M
- CGEN 149.6M
- IPO Year
- EML N/A
- CGEN 2000
- Fundamental
- Price
- EML $23.51
- CGEN $1.29
- Analyst Decision
- EML
- CGEN Strong Buy
- Analyst Count
- EML 0
- CGEN 1
- Target Price
- EML N/A
- CGEN $4.00
- AVG Volume (30 Days)
- EML 6.8K
- CGEN 244.1K
- Earning Date
- EML 05-05-2025
- CGEN 05-19-2025
- Dividend Yield
- EML 1.87%
- CGEN N/A
- EPS Growth
- EML N/A
- CGEN N/A
- EPS
- EML N/A
- CGEN N/A
- Revenue
- EML $272,751,967.00
- CGEN $27,864,000.00
- Revenue This Year
- EML N/A
- CGEN $11.81
- Revenue Next Year
- EML N/A
- CGEN $28.37
- P/E Ratio
- EML $11.13
- CGEN N/A
- Revenue Growth
- EML 5.37
- CGEN N/A
- 52 Week Low
- EML $23.15
- CGEN $1.20
- 52 Week High
- EML $35.03
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- EML 32.83
- CGEN 25.15
- Support Level
- EML $23.16
- CGEN $1.50
- Resistance Level
- EML $25.71
- CGEN $1.53
- Average True Range (ATR)
- EML 0.62
- CGEN 0.07
- MACD
- EML -0.25
- CGEN -0.01
- Stochastic Oscillator
- EML 9.78
- CGEN 0.00
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.